ArticleBioengineering & translational medicine2026
Development of a novel methyl cellulose hydrogel with physiologically relevant controlled ethanol release for cervical dysplasia ablation.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early career innovators shaping the future of bioengineering and translational medicine.Bioengineering & translational medicine · 2026Article
- Preparation and Biomedical Applications of Spherical Cellulose Hydrogels: A Mini-Review.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is a leading cause of death in women in low- and middle-income countries (LMICs) and disproportionately affects women of minority populations in the United States, primarily due to a lack of infrastructural support for specialized care. A promising treatment that meets accessibility requirements is ethyl cellulose (EC)-ethanol ablation-inducing necrotic cell death through application of ethanol to kill precancerous cells. While previous work focused on injecting EC-ethanol to ablate high-grade dysplasia (which can reach depths up to 5 mm below the tissue surface), low-grade dysplasia requires a different delivery method as it is much more superficial (reaching depths of only 1-3 mm). Here, we have developed a topical gel for local ethanol ablation of low-grade dysplasia with minimal damage to healthy cervical tissue. We investigated several gellants, including methyl cellulose (MC), EC, and Pluronic® F-127, to develop an ethanol gel that meets parameters for low cost and topical ease of use. Formulations with F-127 did not form gels with ethanol. Formulations with EC and MC were gel-forming. The MC-based formulations formed more uniform and stable gels that hold their own weight while still being spreadable at both room and body temperatures, key criteria for local cervical application. The optimal formulation contained 70% ethanol, 20% water, and 10% MC. One gram of this formulation represents approximately 5¢ material cost, and formulated gels were stable for at least 1 week when stored at 4, 22, 30, and 37°C. Additionally, the MC gel achieved localized ablation within 5 min after application to cervical cancer cells in vitro. Taken together, we have developed a low-cost, efficacious, MC-based ethanol gel fit for translational testing to treat low-grade cervical dysplasia. This gel may provide a novel treatment option for women in LMICs, without causing major side effects or loss of healthy cervical tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.